Skip to search formSkip to main contentSkip to account menu

SCIO-469

Known as: SCIO 469 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

IndolesTalmapimod
bortezomib/SCIO-469

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
SCIO-469 loaded Microparticles for Osteoarthritis treatment : fluorescence imaging and drug delivery
SUMMARY SCIO-469 loaded microparticles offer a new imaging capability of controlled release technology for the treatment of… 
2010
2010
Topical alpha-selective p 38 MaP kinase inhibition reduces acute skin inflammation in guinea pig satyanarayana
correspondence: satyanarayana Medicherla schering Plough Biopharma, 901 california ave, Palo alto, ca 94304, Usa Tel +1 650 496… 
2010
2010
Mitos cristianos en la poesía no religiosa del grupo del veintisiete
5 
2008
2008
p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma.
Multiple myeloma (MM) is a clonal plasma cell malignancy, which is currently incurable. Therefore, new mono- or combined therapy… 
2006
2006
Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS).
Pro-apoptotic cytokines generated in the medullary microenvironment potentiate ineffective hematopoiesis in MDS. Preclinical… 
2006
2006
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2005
2005
SCIO-469, a Potent and Selective Inhibitor of the p38a MAPK, Inhibits TNFa-Induced Adhesion of Multiple Myeloma Cells to Bone Marrow Stromal Cells Via Downregulation of Chemokines CXCL10/IP-10 and…
Multiple myeloma (MM) is a plasma cell cancer characterized by the accumulation and clonal expansion of malignant cells in the… 
2005
2005
American Society of Hematology State-ofthe-Art Symposium : Myeloma and Lymphoma : Recent Advances in Biology and Therapy
Recent progress in the research on multiple myeloma (MM) demonstrates the tumor-promoting influence of the microenvironment… 
2004
2004
SCIO-469, a Potent and Selective Inhibitor of p38a MAPK, Normalizes the Bone Marrow Microenvironment and Inhibits Multiple Myeloma Cell Proliferation in In Vitro and In Vivo Models.
Despite recent advances in the treatment of multiple myeloma (MM), this disease remains incurable. Accumulating evidence suggest… 
2004
2004
Inhibition of p38 MAPK by SCIO-469 Suppresses TNF Generation and Promotes CD34+ Cell Survival in an In Vitro MDS Cell Culture Model.
Progress in the development of more effective therapeutics for myelodysplastic syndrome (MDS) has been limited by the lack of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)